Reprogramming of Central Carbon Metabolism in Tumor Cells: A Focus on Glycolytic Flux and the Warburg Phenotype

Background: One of the defining hallmarks of cancer is the reprogramming of cellular metabolism to support rapid proliferation, survival in hostile microenvironments, and resistance to therapy. Among these metabolic adaptations, the enhancement of glycolytic flux—even in the presence of oxygen, known as the Warburg effect—has emerged as a central feature of tumor cell bioenergetics. This shift reflects a complex reorganization of central carbon metabolism, enabling cancer cells to meet increased demands for biosynthetic precursors, reducing power, and ATP. Methods and Results: This review provides an integrative analysis of glycolytic reprogramming in tumor cells, highlighting key enzymatic nodes, regulatory mechanisms, and oncogenic signaling pathways that drive the Warburg phenotype. Upregulation of rate-limiting enzymes such as hexokinase 2, phosphofructokinase-1, and pyruvate kinase M2 is accompanied by altered expression and activity of lactate dehydrogenase A and glucose transporters (GLUT1, GLUT3), sustaining high glycolytic throughput. Additionally, tumor microenvironmental factors such as hypoxia, acidosis, and nutrient limitation further amplify glycolytic dependency and lactate export, contributing to immune evasion and metastasis. Therapeutic strategies targeting glycolytic enzymes, lactate transporters, and metabolic signaling regulators are under active investigation, with several agents in preclinical and early clinical development. Conclusion: The reprogramming of central carbon metabolism, particularly the persistent elevation of glycolytic flux despite oxygen availability, represents a fundamental adaptation in cancer biology. Deciphering the molecular drivers and functional consequences of the Warburg effect holds significant promise for the development of metabolism-targeted therapies that selectively disrupt tumor growth while sparing normal cells.